Ex vivo expansion of the highly cytotoxic human natural killer-92 cell-line under current good manufacturing practice conditions for clinical adoptive cellular immunotherapy.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Cytotherapy

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1080/14653240310001523PMID 12850795
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Large-scale preparation of adherent lymphokine-activated killer (A-LAK) cells for adoptive immunotherapy in man

  2004cited by this paper
• Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.

  2002cited by this paper
• Allogeneic bone marrow transplantation with reduced conditioning (RC‐BMT)

  2001cited by this paper
• Cellular Immunotherapy of Malignancies Using the Clonal Natural Killer Cell Line NK-92

  2001cited by this paper
• Factors Regulating the Cytotoxic Activity of the Human Natural Killer Cell Line, NK-92

  2001cited by this paper
• Phase I Trial Of Intravenous Peptide-Pulsed Dendritic Cells in Patients With Metastatic Melanoma

  2001cited by this paper
• Nonmyeloablative hematopoietic cell transplantation

  2001cited by this paper
• Dendritic cells and immunotherapy for malignant disease

  2001cited by this paper
• Phase 1 Study in Patients With Metastatic Melanoma of Immunization With Dendritic Cells Presenting Epitopes Derived From the Melanoma-Associated Antigens MART-1 and gp100

  2000cited by this paper
• Dendritic cell-based immunotherapy of cancer.

  2000cited by this paper
• Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.

  2000cited by this paper
• Non-myeloablative stem cell transplants. Annotation

  2000cited by this paper
• Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.

  2000cited by this paper
• Adoptive cellular therapy.

  2000cited by this paper
• Clinical and biological effects of intraperitoneal injections of recombinant interferon-gamma and recombinant interleukin 2 with or without tumor-infiltrating lymphocytes in patients with ovarian or peritoneal carcinoma.

  2000cited by this paper
• Active Immunization of Humans with Dendritic Cells

  2000cited by this paper
• Non‐myeloablative stem cell transplants

  2000cited by this paper
• Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.

  1999cited by this paper
• Donor lymphocyte infusions.

  1999cited by this paper
• Characterization of Genetically Altered, Interleukin 2-Independent Natural Killer Cell Lines Suitable for Adoptive Cellular Immunotherapy

  1999cited by this paper
• Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer.

  1999cited by this paper
• Immunotherapy of Malignant Melanoma in a SCID Mouse Model Using the Highly Cytotoxic Natural Killer Cell Line NK-92

  1999cited by this paper
• The use of dendritic cells for cancer vaccination.

  1999cited by this paper
• Donor lymphocyte infusion for the treatment of relapse after allogeneic hematopoietic stem cell transplantation.

  1998cited by this paper
• Adjuvant adoptive immunotherapy with tumour-infiltrating lymphocytes and modulated doses of interleukin-2 in 22 patients with melanoma, colorectal and renal cancer, after radical metastasectomy, and in 12 advanced patients

  1998cited by this paper
• Antileukemia activity of a natural killer cell line against human leukemias.

  1998cited by this paper
• Immunotherapy with recombinant human interleukin-2 and recombinant interferon-alpha in lymphoma patients postautologous marrow or stem cell transplantation.

  1997cited by this paper
• Cellular immunotherapy following autologous hematopoietic progenitor cell transplantation.

  1997cited by this paper
• TCR beta-chain variable region-driven selection and massive expansion of HLA-class I-restricted antitumor CTL lines from HLA-A*0201+ melanoma patients.

  1997cited by this paper
• A cytotoxic NK-cell line (NK-92) for ex vivo purging of leukemia from blood.

  1996cited by this paper
• Natural immune reactivity-associated therapeutic response in patients with metastatic renal cell carcinoma receiving tumor-infiltrating lymphocytes and interleukin-2-based therapy.

  1996cited by this paper
• Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.

  1996cited by this paper
• Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.

  1996cited by this paper
• Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.

  1996cited by this paper
• Differential anti-MART-1/MelanA CTL activity in peripheral blood of HLA-A2 melanoma patients in comparison to healthy donors: evidence of in vivo priming by tumor cells.

  1996cited by this paper
• Purging of malignant cells from blood after short ex vivo incubation with NK-92 cells.

  1996cited by this paper
• Production of Human Natural Killer Cells for Adoptive Immunotherapy Using a Computer-Controlled Stirred-Tank Bioreactor

  1996cited by this paper
• Detection and quantification of blood-derived CD8+ T lymphocytes secreting tumor necrosis factor alpha in response to HLA-A2.1-binding melanoma and viral peptide antigens.

  1996cited by this paper
• GRAFT‐VERSUS‐LEUKAEMIA: UNDERSTANDING AND USING THE ALLOIMMUNE RESPONSE TO TREAT HAEMATOLOGICAL MALIGNANCIES

  1996cited by this paper
• Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets

  1996cited by this paper
• Natural Killer Cell Proliferation Is Dependent on Human Serum and Markedly Increased Utilizing an Enriched Supplemented Basal Medium

  1995cited by this paper
• Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia?

  1995cited by this paper
• Interleukin-2 gene therapy in a patient with glioblastoma.

  1995cited by this paper
• Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells.

  1994cited by this paper
• Large scale ex vivo expansion and activation of human natural killer cells for autologous therapy.

  1994cited by this paper
• Reversal of acute myelogenous leukemia in humanized SCID mice using a novel adoptive transfer approach.

  1994cited by this paper
• Activation of T lymphocytes for the adoptive immunotherapy of cancer

  1994cited by this paper

• Targeting SHP‐1‐Mediated Inhibition of STAT3 and ERK Signalling Pathways Rescues the Hyporesponsiveness of MHC‐I‐Deficient NK‐92MI

  2025cites this paper
• CAR-NK cells: harnessing the power of natural killers for advanced cancer therapy

  2025cites this paper
• Does a natural killer need a CAR?

  2025cites this paper
• Adoptive transfer of natural killer cells in therapeutic treatment of COVID-19 patients

  2025cites this paper
• Dark NKnight rising: a current perspective on NK cell and CAR-NK cell therapy.

  2025cites this paper
• Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors.

  2024cites this paper
• Chimeric antigen receptor natural killer cell therapy: A systematic review of preclinical studies for hematologic and solid malignancies.

  2024cites this paper
• Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies

  2024cites this paper
• Bispecific immune cell engager enhances the anticancer activity of CD16+ NK cells and macrophages in vitro, and eliminates cancer metastasis in NK humanized NOG mice

  2024cites this paper
• Manufacturing CAR-NK against tumors: Who is the ideal supplier?

  2024cites this paper
• Successful expansion and cryopreservation of human natural killer cell line NK-92 for clinical manufacturing

  2024cites this paper
• Targeting natural killer cells: from basic biology to clinical application in hematologic malignancies

  2024cites this paper
• Establishment of humanized mice and its application progress in cancer immunotherapy.

  2023cites this paper
• Kinetics of NK-92 growth and functionality in pseudo-static cultures

  2023cites this paper
• Manipulating NK cellular therapy from cancer to invasive fungal infection: promises and challenges

  2023cites this paper
• Addressing Natural Killer Cell Dysfunction and Plasticity in Cell-Based Cancer Therapeutics

  2023cites this paper
• Natural killer cells in clinical development as non-engineered, engineered, and combination therapies

  2022cites this paper
• NK-92 cells retain vitality and functionality when grown in standard cell culture conditions

  2022cites this paper
• Roles of natural killer cells in immunity to cancer, and applications to immunotherapy

  2022cites this paper
• iPSCs in NK Cell Manufacturing and NKEV Development

  2022cites this paper
• Adoptive Cell Therapy for T-Cell Malignancies

  2022cites this paper
• Vitamin combination promotes ex vivo expansion of NK-92 cells by reprogramming glucose metabolism

  2022cites this paper
• Cellular Immunotherapy Targeting Cancer Stem Cells: Preclinical Evidence and Clinical Perspective

  2021cites this paper
• NK Cell-Mediated Eradication of Ovarian Cancer Cells with a Novel Chimeric Antigen Receptor Directed against CD44

  2021cites this paper
• The emerging role of off-the-shelf engineered natural killer cells in targeted cancer immunotherapy

  2021cites this paper
• In Vitro Evaluation of CD276-CAR NK-92 Functionality, Migration and Invasion Potential in the Presence of Immune Inhibitory Factors of the Tumor Microenvironment

  2021cites this paper
• NK-Cell Biofactory as an Off-the-Shelf Cell-based Vector for Targeted In Situ Synthesis of Engineered Proteins.

  2021cites this paper
• Equipping Natural Killer Cells with Cetuximab through Metabolic Glycoengineering and Bioorthogonal Reaction for Targeted Treatment of KRAS Mutant Colorectal Cancer.

  2021cites this paper
• Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy

  2021cites this paper
• HLA Class I Knockout Converts Allogeneic Primary NK Cells Into Suitable Effectors for “Off-the-Shelf” Immunotherapy

  2021cites this paper
• Manufacturing of natural killer cells for treating solid malignancies

  2020cites this paper
• Recent Advances in the Use of NK Cells Against Cancer

  2020cites this paper
• CAR-expressing NK cells for cancer therapy: a new hope.

  2020cites this paper
• NKp30 ‐ A prospective target for new cancer immunotherapy strategies

  2020cites this paper
• NK cells for cancer immunotherapy

  2020cites this paper
• NK Cell-Based Immunotherapy in Renal Cell Carcinoma

  2020cites this paper
• Current strategies for adoptive immunotherapy for cancer: ”Off-the-shelf” immune cells

  2020cites this paper
• Genome engineering of induced pluripotent stem cells to manufacture natural killer cell therapies

  2020influential citation
• Renal cell tumors convert natural killer cells to a proangiogenic phenotype

  2020cites this paper
• The role of natural killer cell in gastrointestinal cancer: killer or helper

  2020cites this paper
• Irradiated chimeric antigen receptor engineered NK-92MI cells show effective cytotoxicity against CD19+ malignancy in a mouse model.

  2020cites this paper
• CAR-Based Strategies beyond T Lymphocytes: Integrative Opportunities for Cancer Adoptive Immunotherapy

  2019cites this paper
• Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

  2019cites this paper
• Beyond CAR T Cells: Other Cell-Based Immunotherapeutic Strategies Against Cancer

  2019cites this paper
• Preclinical Assessment of Suitable Natural Killer Cell Sources for Chimeric Antigen Receptor Natural Killer–Based “Off-the-Shelf” Acute Myeloid Leukemia Immunotherapies

  2019cites this paper
• Magnetic Nanoparticles Attached to the NK Cell Surface for Tumor Targeting in Adoptive Transfer Therapies Does Not Affect Cellular Effector Functions

  2019cites this paper
• Natural killer cells and cancer therapy, what we know and where we are going.

  2019cites this paper
• Title: Engineering the TGFβ receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma

  2019cites this paper
• Functional Assessment for Clinical Use of Serum-Free Adapted NK-92 Cells

  2019cites this paper
• Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy

  2019cites this paper
• State of the Art of Natural Killer Cell Imaging: A Systematic Review

  2019cites this paper
• CD56 expression in breast cancer induces sensitivity to natural killer-mediated cytotoxicity by enhancing the formation of cytotoxic immunological synapse

  2019cites this paper
• Interaction Kinetics with Transcriptomic and Secretory Responses of CD19 CAR Natural Killer Cell Therapy in CD20 Resistant Non-Hodgkin Lymphoma

  2019cites this paper
• NK Cell-Based Immunotherapy for Hematological Malignancies

  2019cites this paper
• NK Cell and NKT Cell Immunotherapy

  2018cites this paper
• Prospect of Natural Killer Cells in Cancer Imunotherapy

  2018cites this paper
• Bortezomib improves adoptive carbonic anhydrase IX‑specific chimeric antigen receptor‑modified NK92 cell therapy in mouse models of human renal cell carcinoma.

  2018cites this paper
• 19F-MRI to Monitor Therapeutic Cell Migration and Distribution

  2018cites this paper
• Engineering the TGFβ Receptor to Enhance the Therapeutic Potential of Natural Killer Cells as an Immunotherapy for Neuroblastoma

  2018cites this paper
• Reformation in chimeric antigen receptor based cancer immunotherapy: Redirecting natural killer cell.

  2018cites this paper
• Assessing the immunomodulatory effects of Ganoderma lucidum and Coriolus versicolor on the cancer killing capacity of natural killer cells

  2018cites this paper
• Donor Natural Killer Cells and Their Therapeutic Potential in Allogeneic Hematopoietic Stem Cell Transplantation

  2017cites this paper
• Recent advances of immune checkpoint in breast cancer

  2017cites this paper
• Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies

  2017cites this paper
• Novel Strategy to Expand Super-Charged NK Cells with Significant Potential to Lyse and Differentiate Cancer Stem Cells: Differences in NK Expansion and Function between Healthy and Cancer Patients

  2017cites this paper
• NK-92 cell, another ideal carrier for chimeric antigen receptor.

  2017cites this paper
• Chimeric antigen receptor (CAR)-transduced natural killer cells in tumor immunotherapy

  2017cites this paper
• Licensed to Kill: Towards Natural Killer Cell Immunotherapy

  2017cites this paper
• NK Cell Subsets in Health and Disease: New Developments

  2017cites this paper
• Engineering Hematopoietic Cells for Cancer Immunotherapy: Strategies to Address Safety and Toxicity Concerns

  2016cites this paper
• Immunotherapeutic approaches for the treatment of childhood, adolescent and young adult non‐Hodgkin lymphoma

  2016cites this paper
• Potential Cancer Prevention and Treatment by Silencing the Killer Cell Immunoglobulin-like Receptor Gene in Natural Killer Cells Derived from Induced Pluripotent Stem Cells.

  2016cites this paper
• NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy

  2016cites this paper
• Immune Checkpoint Modulators: An Emerging Antiglioma Armamentarium

  2016cites this paper
• Strategies and developments of immunotherapies in osteosarcoma.

  2016cites this paper
• A Cytokine Cocktail Augments the Efficacy of Adoptive NK-92 Cell Therapy Against Mouse Xenografts of Human Cancer.

  2016cites this paper
• Strategies and developments of immunotherapies in osteosarcoma (Review)

  2016cites this paper
• Manufacturing Natural Killer Cells as Medicinal Products

  2016cites this paper
• Expanded and armed natural killer cells for cancer treatment.

  2016cites this paper
• Natural Killer Cells for Therapy of Leukemia

  2016cites this paper
• Die Nutzung natürlicher Killerzellen für die Therapie des Melanoms

  2015cites this paper
• Mechanism and efficacy of a GD2-specific immunotherapy using NK cells

  2015cites this paper
• Using NK Cell Mediated Cytolysis to Trigger Adaptive Immune Responses

  2015cites this paper
• Exploiting natural anti-tumor immunity for metastatic renal cell carcinoma

  2015cites this paper
• In vitro exposure of NK-92 cells to serum from patients with non-small cell lung cancer impairs their cytotoxicity.

  2015cites this paper
• Exploiting natural killer cells for therapy of melanoma

  2015cites this paper
• The role of checkpoints in the treatment of GBM

  2015cites this paper
• Advances in clinical NK cell studies: Donor selection, manufacturing and quality control

  2015cites this paper
• Natural Killer Cell-Based Therapies Targeting Cancer: Possible Strategies to Gain and Sustain Anti-Tumor Activity

  2015cites this paper
• Revving up Natural Killer Cells and Cytokine-Induced Killer Cells Against Hematological Malignancies

  2015cites this paper
• Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma

  2015cites this paper
• Potential Use of Natural Killer Cell Transfer Therapy in the Perioperative Period to Improve Oncologic Outcomes

  2015cites this paper
• Evaluation of therapeutic effects of natural killer (NK) cell‐based immunotherapy in mice using in vivo apoptosis bioimaging with a caspase‐3 sensor

  2014cites this paper
• Improving the Outcome of Leukemia by Natural Killer Cell-Based Immunotherapeutic Strategies

  2014cites this paper
• Natural Killer Cells for Cancer Immunotherapy: Pluripotent Stem Cells-Derived NK Cells as an Immunotherapeutic Perspective

  2014cites this paper
• Treatment of patients with advanced cancer with the natural killer cell line NK-92.

  2013cites this paper
• Reciprocal crosstalk between dendritic cells and natural killer cells under the effects of PGE2 in immunity and immunopathology

  2013cites this paper
• Liver natural killer cell inoculum for liver transplantation with hepatocellular carcinoma

  2013cites this paper
• Cellular therapy of cancer with natural killer cells-where do we stand?

  2013cites this paper
• Natural killer cells: a review of manufacturing and clinical utility

  2013cites this paper